MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data
The final decision to pursue such a Phase 3 study will be based on an analysis of the final data set, including rPFS, when available.
- The final decision to pursue such a Phase 3 study will be based on an analysis of the final data set, including rPFS, when available.
- MacroGenics continues to enroll a Phase 1/2 dose escalation study of vobra duo in combination with lorigerlimab in patients with various advanced solid tumors.
- The Company anticipates commencing a dose expansion study of this combination in mCRPC and at least one additional indication in 2024.
- The HEAT study, an investigator-sponsored, randomized Phase 2 clinical trial being conducted by MacroGenics’ academic collaborators, is ongoing.